CL2021000942A1 - Anticuerpos anti-npr1 y usos relacionados. - Google Patents
Anticuerpos anti-npr1 y usos relacionados.Info
- Publication number
- CL2021000942A1 CL2021000942A1 CL2021000942A CL2021000942A CL2021000942A1 CL 2021000942 A1 CL2021000942 A1 CL 2021000942A1 CL 2021000942 A CL2021000942 A CL 2021000942A CL 2021000942 A CL2021000942 A CL 2021000942A CL 2021000942 A1 CL2021000942 A1 CL 2021000942A1
- Authority
- CL
- Chile
- Prior art keywords
- npr1
- related uses
- npr1 antibodies
- antibodies
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862749557P | 2018-10-23 | 2018-10-23 | |
| US201862755720P | 2018-11-05 | 2018-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021000942A1 true CL2021000942A1 (es) | 2022-02-04 |
Family
ID=68732036
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021000942A CL2021000942A1 (es) | 2018-10-23 | 2021-04-15 | Anticuerpos anti-npr1 y usos relacionados. |
| CL2023001377A CL2023001377A1 (es) | 2018-10-23 | 2023-05-12 | Anticuerpos anti-npr1 y usos de los mismos |
| CL2024000378A CL2024000378A1 (es) | 2018-10-23 | 2024-02-07 | Anticuerpos anti-npr1 y usos de los mismos. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001377A CL2023001377A1 (es) | 2018-10-23 | 2023-05-12 | Anticuerpos anti-npr1 y usos de los mismos |
| CL2024000378A CL2024000378A1 (es) | 2018-10-23 | 2024-02-07 | Anticuerpos anti-npr1 y usos de los mismos. |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US11306148B2 (enExample) |
| EP (1) | EP3870612A2 (enExample) |
| JP (3) | JP7439076B2 (enExample) |
| KR (1) | KR20210082207A (enExample) |
| CN (1) | CN112805303B (enExample) |
| AU (1) | AU2019368196B2 (enExample) |
| CA (1) | CA3115102A1 (enExample) |
| CL (3) | CL2021000942A1 (enExample) |
| CO (1) | CO2021006663A2 (enExample) |
| IL (1) | IL281297B1 (enExample) |
| MX (2) | MX2021004284A (enExample) |
| MY (1) | MY205168A (enExample) |
| PH (1) | PH12021550255A1 (enExample) |
| SG (1) | SG11202101037QA (enExample) |
| WO (1) | WO2020086406A2 (enExample) |
| ZA (1) | ZA202100714B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210082207A (ko) | 2018-10-23 | 2021-07-02 | 리제너론 파아마슈티컬스, 인크. | 항-npr1 항체 및 이의 용도 |
| US11066469B2 (en) | 2019-06-12 | 2021-07-20 | Novartis Ag | Natriuretic peptide receptor 1 antibodies and methods of use |
| EP4259661A1 (en) | 2020-12-14 | 2023-10-18 | Novartis AG | Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof |
| US12325752B2 (en) | 2020-12-18 | 2025-06-10 | Regeneron Pharmaceuticals, Inc. | Immunoglobulin proteins that bind to NPR1 agonists |
| US12281161B2 (en) | 2021-07-28 | 2025-04-22 | Trustees Of Boston University | Polypeptides and uses thereof |
| CN118159290A (zh) | 2021-10-11 | 2024-06-07 | 瑞泽恩制药公司 | 通过施用抗npr1抗体来影响血液动力学变化的方法 |
| JP2024542823A (ja) * | 2021-12-06 | 2024-11-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アンタゴニスト抗ｎｐｒ１抗体およびその使用方法 |
| WO2023187657A1 (en) | 2022-03-30 | 2023-10-05 | Novartis Ag | Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies |
| AU2024287056A1 (en) * | 2023-06-08 | 2025-12-11 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-npr1 antibody and pharmaceutical use thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20080214437A1 (en) * | 2002-09-06 | 2008-09-04 | Mohapatra Shyam S | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| US20100310561A1 (en) * | 2007-06-06 | 2010-12-09 | Boehringer Ingelheim International Gmbh | Natriuretic fusion proteins |
| WO2010065293A1 (en) | 2008-12-03 | 2010-06-10 | Boehringer Ingelheim Pharmaceuticals Inc. | Antibodies for guanylyl cyclase receptors |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| AU2010273585B2 (en) | 2009-07-13 | 2015-04-23 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
| SMT202600080T1 (it) | 2010-02-08 | 2026-03-09 | Regeneron Pharma | Topo con catena leggera comune |
| US10184942B2 (en) * | 2011-03-17 | 2019-01-22 | University Of South Florida | Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer |
| US9451770B2 (en) | 2012-06-08 | 2016-09-27 | Charles Despres | Method of activating immune response in plants |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| WO2016131943A1 (en) * | 2015-02-20 | 2016-08-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of obesity and complications arising therefrom including type 2 diabetes |
| WO2017209553A2 (ko) | 2016-06-03 | 2017-12-07 | 사회복지법인 삼성생명공익재단 | 환자 유래 세포를 이용한 항체 스크리닝 방법 |
| US20190248888A1 (en) * | 2016-10-20 | 2019-08-15 | Regeneron Pharmaceuticals, Inc. | Methods of lowering blood glucose levels |
| US20190135804A1 (en) | 2017-11-03 | 2019-05-09 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Compositions and methods for the inhibition of pruritus |
| KR20210082207A (ko) | 2018-10-23 | 2021-07-02 | 리제너론 파아마슈티컬스, 인크. | 항-npr1 항체 및 이의 용도 |
| EP3898700A1 (en) | 2018-12-18 | 2021-10-27 | Novartis AG | Reversal binding agents for anti-factor xi/xia antibodies and uses thereof |
| US11066469B2 (en) | 2019-06-12 | 2021-07-20 | Novartis Ag | Natriuretic peptide receptor 1 antibodies and methods of use |
| EP4259661A1 (en) | 2020-12-14 | 2023-10-18 | Novartis AG | Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof |
| US12325752B2 (en) | 2020-12-18 | 2025-06-10 | Regeneron Pharmaceuticals, Inc. | Immunoglobulin proteins that bind to NPR1 agonists |
| JP2024542823A (ja) | 2021-12-06 | 2024-11-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アンタゴニスト抗ｎｐｒ１抗体およびその使用方法 |
-
2019
- 2019-10-18 KR KR1020217015469A patent/KR20210082207A/ko active Pending
- 2019-10-18 MY MYPI2021001138A patent/MY205168A/en unknown
- 2019-10-18 CN CN201980065187.4A patent/CN112805303B/zh active Active
- 2019-10-18 US US16/657,000 patent/US11306148B2/en active Active
- 2019-10-18 MX MX2021004284A patent/MX2021004284A/es unknown
- 2019-10-18 JP JP2021522004A patent/JP7439076B2/ja active Active
- 2019-10-18 WO PCT/US2019/057033 patent/WO2020086406A2/en not_active Ceased
- 2019-10-18 SG SG11202101037QA patent/SG11202101037QA/en unknown
- 2019-10-18 AU AU2019368196A patent/AU2019368196B2/en active Active
- 2019-10-18 CA CA3115102A patent/CA3115102A1/en active Pending
- 2019-10-18 EP EP19812875.3A patent/EP3870612A2/en active Pending
-
2021
- 2021-02-02 ZA ZA2021/00714A patent/ZA202100714B/en unknown
- 2021-02-03 PH PH12021550255A patent/PH12021550255A1/en unknown
- 2021-03-07 IL IL281297A patent/IL281297B1/en unknown
- 2021-04-14 MX MX2024011444A patent/MX2024011444A/es unknown
- 2021-04-15 CL CL2021000942A patent/CL2021000942A1/es unknown
- 2021-05-21 CO CONC2021/0006663A patent/CO2021006663A2/es unknown
-
2022
- 2022-03-10 US US17/692,084 patent/US11820826B2/en active Active
-
2023
- 2023-05-12 CL CL2023001377A patent/CL2023001377A1/es unknown
- 2023-10-11 US US18/485,241 patent/US20240059780A1/en not_active Abandoned
-
2024
- 2024-02-07 CL CL2024000378A patent/CL2024000378A1/es unknown
- 2024-02-13 JP JP2024019151A patent/JP7713051B2/ja active Active
- 2024-05-31 US US18/680,910 patent/US20240309103A1/en active Pending
-
2025
- 2025-07-10 JP JP2025116272A patent/JP2025148445A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021000942A1 (es) | Anticuerpos anti-npr1 y usos relacionados. | |
| SA521420953B1 (ar) | بروتين ربط مولد ضد مضاد لـمولد ضد ظهاري ذو 6 أغشية انتقالية من البروستاتا 1 | |
| CL2018002490A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866) | |
| EA202090247A1 (ru) | Антитела против cd166 и их применения | |
| AR111362A1 (es) | Anticuerpos anti-ilt4 y fragmentos de unión a antígeno | |
| BR112019000770A2 (pt) | proteínas de ligação semelhantes a anticorpos biespecíficos que se ligam especificamente às cd3 e cd123 | |
| AR101846A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
| PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
| ES2676023T3 (es) | Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso | |
| CU20180135A7 (es) | Anticuerpos monoclonales aislados que compiten por la unión a tau con el anticuerpo 3d6 | |
| EA201892522A1 (ru) | Днк-моноклональные антитела, нацеленные на молекулы контрольных точек | |
| CO2021014153A2 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
| HRP20240704T1 (hr) | Postupci za predviđanje korisnosti neoantigena za imunoterapiju | |
| SA522440646B1 (ar) | أجسام مضادة ترتبط بـ siglec15 واستخداماتها | |
| AR128031A1 (es) | Anticuerpos agonistas anti-ltbr y anticuerpos biespecíficos que los comprenden | |
| JOP20200215A1 (ar) | الأجسام المضادة لـ PHF-Tau المضاد واستخداماتها | |
| CL2018003072A1 (es) | Anticuerpos anti-basigin humanizados y uso de los mismos. | |
| MX2021015356A (es) | Anticuerpos y fragmentos de anticuerpos anti-epcam condicionalmente activos, sus inmunoconjugados y usos de estos. | |
| PE20191319A1 (es) | Anticuerpos novedosos contra el factor xi y sus usos | |
| EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
| BR112022005410A2 (pt) | Métodos e composições compreendendo um anticorpo monoclonal anti-ctla4 com proteínas de célula hospedeira reduzidas e estabilidade de polissorbato 80 aumentada | |
| CO2021008755A2 (es) | Anticuerpo que se une a vegf y a il-1beta y métodos de utilización | |
| CL2021001104A1 (es) | Anticuerpo monoclonal que se une específicamente al antígeno cd20 | |
| UY37752A (es) | Proteínas de unión al antígeno anti-jagged1 | |
| BR112022004570A2 (pt) | Terapia de combinação com anticorpos entpd2 e cd73 |